Rezo Therapeutics is a San Francisco, CA-based biotechnology company pursuing an integrated approach to drug discovery. The company’s Sequence to Systems to Drugs (SSD) platform integrates proteomics, genetics, structural biology, chemistry and bioinformatics to create maps of molecular disease networks. Rezo’s initial focus is in oncology, with plans to explore additional therapeutic areas through collaborations and partnerships. The founding team’s work originated at the Quantitative Biosciences Institute (QBI) at UCSF. Leadership includes CEO Nevan Krogan and co-founders Kevan Shokat, Ph.D., and George Scangos, Ph.D. The company recently raised capital to expand operations and advance its development efforts.

Total raised

$78M

Funding rounds

1

Latest round

Series A

Latest activity

Nov 2022